Human Genome Sciences, Inc. - Product Pipeline Review - 2012 New Report


Naperville, IL -- (SBWire) -- 09/28/2012 --Human Genome Sciences, Inc. - Product Pipeline Review - 2012 provides data on the Human Genome Sciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.


- Human Genome Sciences, Inc. - Brief Human Genome Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Human Genome Sciences, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Human Genome Sciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Human Genome Sciences, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Human Genome Sciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Human Genome Sciences, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Human Genome Sciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Human Genome Sciences, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Human Genome Sciences, Inc. and identify potential opportunities in those areas.


Current R&D Portfolio of Human Genome Sciences, Inc.; Human Genome Sciences, Inc. - Key Therapeutics; Human Genome Sciences, Inc. - Pipeline Overview and Promising Molecules; Human Genome Sciences, Inc. - News; Human Genome Sciences, Inc. - Latest Updates; Human Genome Sciences, Inc. - Pipeline; Human Genome Sciences, Inc. - Discontinued/Dormant Projects

To view table of contents for this market report please visit:

Media Relations Contact

Web master

View this press release online at: